Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Metadata
Title
Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors
Publication date
01-02-2010
Published in
Cancer Immunology, Immunotherapy / Issue 2/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0757-9

Other articles of this Issue 2/2010

Cancer Immunology, Immunotherapy 2/2010 Go to the issue

Letter to the editor

Response to Dr Derhovanessian “Impact of cytomegalovirus infection on immune signatures in cancer patients”

Original Article

Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection

Original Article

Systemic dysregulation of CEACAM1 in melanoma patients

Review

Multimer technologies for detection and adoptive transfer of antigen-specific T cells

Original Article

Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility

Erratum

Erratum to: Amyloid precursor-like protein 2 association with HLA class I molecules
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits